recombinant influenza hemagglutinin + Advax1

This is a **combination vaccine formulation** consisting of recombinant influenza hemagglutinin (HA)—the main surface glycoprotein antigen from the influenza virus, produced using recombinant DNA technology—and **Advax1**, a proprietary adjuvant based on delta inulin microparticles. The recombinant HA component elicits strain-specific anti-influenza antibody responses, while Advax1 functions as an *immunomodulatory adjuvant* that enhances the immune response to the protein antigen with a minimal inflammatory profile. Advax1 (delta inulin) is known to enhance both humoral and cellular immunity and has demonstrated safety and tolerability in human clinical trials for various viral vaccines, including influenza. This combination is primarily investigated as a **prophylactic influenza vaccine** candidate, designed to improve immunogenicity and potentially broaden immune responses beyond that of traditional influenza vaccines.

Other names

recombinant influenza HA + Advax1recombinant influenza hemagglutinin + Advax-1